Executive Intelligence

Alex Zhavoronkov

Founder

Alex Zhavoronkov is listed as a founder of Insilico Medicine based in Hong Kong on Brel Digital’s verified company intelligence record.

Company Intelligence Official Website
In this profile

Quick Facts

  • Role Founder
  • Company Insilico Medicine
  • Country Hong Kong
  • Industry AI in Healthcare
  • Founded 2014
  • Known For Insilico's July 2026 Phase III initiation for Rentosertib — an AI-discovered TNIK inhibitor for IPF published…
  • Status Active
  • Last Reviewed Jul 2026

Executive Summary

Alex Zhavoronkov appears in Brel Digital’s verified company_founders attribution for Insilico Medicine based in Hong Kong in the Healthcare sector. This profile records that founder relationship using sources already on file for the company. Personal biography details that are not evidenced in those sources are omitted. Company context (from the verified Insilico Medicine profile): Clinical-stage generative AI biotechnology company advancing Rentosertib and a broad AI-discovered pipeline Why the company matters (verified company field): Insilico's July 2026 Phase III initiation for Rentosertib — an AI-discovered TNIK inhibitor for IPF published in Nature Biotechnology and Nature Medicine — is among the clearest late-stage validations of end-to-end generative AI drug discovery. Official company website on file: https://insilico.com. Readers should consult that site and the Sources section for primary evidence. Brel Digital does not invent prior roles, education, funding history, or awards for founder profiles. Where additional verified public leadership pages become available, this profile should be deepened in a subsequent editorial review.

Career Timeline

Verified company milestones linked to this executive’s organization.

  1. 2014 Company founded

    Insilico Medicine was founded in 2014 per the company profile source on file.

    Source
  2. 2014 Development

    2014: Insilico Medicine founded; Alex Zhavoronkov is founder and chief executive officer.

    Source
  3. 2023 Development

    June 27, 2023: First generative AI-designed drug entered Phase II trials with first patients dosed (Rentosertib program).

    Source
  4. 2026 Development

    July 7, 2026: Insilico initiated Phase III clinical trial for Rentosertib (ISM001-055), generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis.

    Source

Connected Company

Connected Products

Connected Reports

Connected Insights

Industry Intelligence

AI in Healthcare Open industry

Alex Zhavoronkov appears in Brel Digital’s verified company_founders attribution for Insilico Medicine based in Hong Kong in the Healthcare sector. This profile records that founder relationship using sources already on file for the company. Personal biography details that are not evidenced in those sources are omitted.

Company context (from the verified Insilico Medicine profile): Clinical-stage generative AI biotechnology company advancing Rentosertib and a broad AI-discovered pipeline

Why the company matters (verified company field): Insilico's July 2026 Phase III initiation for Rentosertib — an AI-discovered TNIK inhibitor for IPF published in Nature Biotechnology and Nature Medicine — is among the clearest late-stage validations of end-to-end generative AI drug discovery.

Official company website on file: https://insilico.com. Readers should consult that site and the Sources section for primary evidence.

Brel Digital does not invent prior roles, education, funding history, or awards for founder profiles. Where additional verified public leadership pages become available, this profile should be deepened in a subsequent editorial review.

Sources and references

This article draws on publicly available company information, official websites, filings, interviews, announcements, and other cited sources. Information may change over time.

Request a correction if you represent this company or believe information is inaccurate.

The AI Brief

Founder and company intelligence, weekly.

Subscribe